-
RNA interference drugs silence specific genes. Investigational drug silences the PLK1 gene involved in tumor growth. Most patients tolerated the drug well; some showed therapeutic benefit. WASHINGTON, D.C. — Early results from a phase I, first in-human study indicate that a potential new class...
Posted to
News
by
AACR News
on
Tue, Apr 9 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, Annual Meeting, AACR Annual Meeting 2013, 2013 Annual Meeting, phase I, RNA interference, Dr. Ramesh K. Ramanathan, RNAi
-
Statement calls for greater efforts in smoking cessation. Tobacco use should be evaluated as a confounding factor in clinical trials. Surveys show tobacco use is often not measured. WASHINGTON, D.C. — An American Association for Cancer Research (AACR) statement calls on the oncology community to...
Posted to
News
by
AACR News
on
Tue, Apr 9 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, tobacco, smoking, Clinical Cancer Research, policy statement, clinical trials, Annual Meeting, AACR Annual Meeting 2013, 2013 Annual Meeting, confounding factor
-
Cisplatin-resistant non-small cell lung cancer cells expressed high levels of hyperactivated PARP1. Cells succumbed to PARP inhibitors in vitro. PARP inhibitor slowed cisplatin-resistant tumor growth in mice. PHILADELPHIA — Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy...
Posted to
News
by
AACR News
on
Wed, Apr 3 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Research, journal, non-small cell lung cancer, NSCLC, cisplatin, PARP1, PARP inhibitor, cisplatin resistance, PAR, Dr. Guido Kroemer
-
Ganetespib killed ALK-driven NSCLC cell lines more effectively than crizotinib. Displayed greater antitumor activity and prolonged survival in a mouse model. Potential as a new option for treating ALK-dependent lung cancers. PHILADELPHIA — A drug that indirectly impairs the function of several...
Posted to
News
by
AACR News
on
Tue, Mar 26 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Discovery, journal, non-small cell lung cancer, anaplastic lymphoma kinase, ALK, NSCLC, ganetespib, resistance, crizotinib, Dr. David Proia
-
Beneficial effect of genetically engineered antitumor T cells was transient. Functionality of T cells changed over time. Strategies are needed to sustain antitumor functionality. PHILADELPHIA — Scientists have characterized how the functionality of genetically engineered T cells administered...
Posted to
News
by
AACR News
on
Thu, Mar 21 2013
Filed under:
Filed under: Press Releases, Research, Treatment, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, journal, immunotherapy, Dr. James R. Heath, T-cells, cell-based immunotherapy
-
Levels of 13 genes elevated in unaffected breasts of women with hormone receptor-negative breast cancer. Eight of the genes were associated with lipid metabolism. Ability to identify those at risk may help tailor prevention strategies. PHILADELPHIA — The overexpression or underexpression of a newly...
Posted to
News
by
AACR News
on
Tue, Mar 19 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, prevention, Cancer Prevention Research, genetics, journal, hormone receptor-negative breast cancer, hormone receptor-positive breast cancer, breast cancer risk, Dr. Seema A. Khan, lipid metabolism
-
MYCN gene is commonly amplified in neuroblastoma and associated with poor prognosis. A BET bromodomain inhibitor downregulated MYCN expression. The drug prolonged survival in three animal models of MYCN-amplified neuroblastoma. PHILADELPHIA — Neuroblastoma, the most common malignant tumor of early...
Posted to
News
by
AACR News
on
Thu, Feb 21 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, Stand Up To Cancer, SU2C, journal, Pediatric cancer, childhood cancer, neuroblastoma, biomarker, MYCN, Dr. Kimberly Stegmaier, BET bromodomain inhibitors
-
Preclinical combination of an EGFR inhibitor and a COX-2 inhibitor was effective. Advanced oral precancerous lesions were eliminated in three patients. Drug combination could be a new strategy to prevent head and neck cancers. PHILADELPHIA — A new drug combination shows promise in reducing the...
Posted to
News
by
AACR News
on
Tue, Feb 19 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, journal, high-risk, squamous cell carcinoma, head and neck cancer, clinical research, precancer, combination, Dr. Dong Moon Shin, oral precancerous lesions
-
-
Mice deficient in PTEN in the prostate developed stable precancers. Androgen deprivation promoted progression to invasive prostate cancer. Patients with PTEN-deficient prostate precancers may not benefit from androgen deprivation chemoprevention therapy. PHILADELPHIA — The use of androgen deprivation...
Posted to
News
by
AACR News
on
Thu, Dec 20 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, cancer prevention, American Association for Cancer Research, prevention, genetics, Cancer Discovery, prostate cancer, journal, Dr. Thomas R. Roberts, precancer, androgen deprivation therapy
-
The mTORC1 inhibitor everolimus is used to treat various medical conditions. Everolimus prevented disease development in a mouse model of Myc-driven lymphoma. Treatment led to tumor regression in mice by inducing cellular senescence. PHILADELPHIA — Drugs that are used in the clinic to treat some...
Posted to
News
by
AACR News
on
Fri, Dec 14 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, journal, Everolimus, Target, Myc, Dr. Grant A. McArthur, mTORC1 inhibitor
-
High-throughput screen identified several drug combinations effective in vitro. Some combinations were effective against cell lines resistant to single agent used clinically. PHILADELPHIA — A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol...
Posted to
News
by
AACR News
on
Thu, Dec 13 2012
Filed under:
Filed under: Press Releases, Research, Treatment, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, journal, skin cancer, Dr. David F. Stern
-
HER2 mutations occurred separately from HER2 gene amplification and DNA sequencing is required to detect them. HER2 mutations are rare but can be immediately treated with existing drugs. Phase II study using neratinib to treat HER2 mutations is under way. SAN ANTONIO — An analysis of data from...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, genetics, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, therapeutic target, neratinib, breast cancer genome, Dr. Ron Bose, HER2 mutations
-
Safety profile was consistent with previous trials of bevacizumab. More understanding of triple-negative breast cancer is still needed. Final overall survival data are expected in 2013. SAN ANTONIO — Patients who received one year of bevacizumab in addition to chemotherapy for the postsurgical...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, triple-negative breast cancer, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, bevacizumab, Dr. David Cameron, BEATRICE study
-
Eribulin showed trend toward improved overall survival versus capecitabine. Eribulin showed greater activity in certain subsets of patients. Researchers are still gathering quality-of-life data. SAN ANTONIO — A phase III multicenter study of eribulin mesylate in women with previously treated metastatic...
Posted to
News
by
AACR News
on
Fri, Dec 7 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, metastatic breast cancer, capecitabine, Dr. Peter A. Kaufman, eribulin